20:04 PM

Perry Receives $1 Million Grant to Study Repurposing Chemotherapeutic Agent

John Perry, PhD, Divsion of Hematology/Oncology/BMT at Children's Mercy Kansas City, was awarded a $1,000,000 grant by Braden's Hope for Childhood Cancer for a three-year study named, “Overcoming therapeutic resistance by repurposing a classic chemotherapeutic drug as a targeted therapy to reactivate anti-cancer immunity.”  

In contrast to current clinical practice of using toxic drugs at or near the maximum tolerated dose, which results in severe long-term side effects, this project will test the potentially transformative idea that drugs currently approved for cancer therapy can be used in a targeted manner to reactivate anti-cancer immunity against the cells responsible for relapse.

Dr. Perry is a faculty member of the Children's Research Institute at Children's Mercy and is Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine and the University of Kansas Medical Center.


Children’s Mercy Kansas City is ranked as one of “America's Best Children's Hospitals” in nine specialties rated by U.S. News & World Report and has received MagnetTM recognition for excellence in nursing services five consecutive times. With 386 licensed beds and a medical staff of more than 750 pediatric subspecialists, we care for children from all 50 states and from around the world. In addition, our leadership in pediatric genomic medicine and individualized pediatric therapeutics is driving research and innovation in neonatology, nephrology, endocrinology, gastroenterology, neurology, heart, cancer and other subspecialties to transform outcomes for children. Children’s Mercy also is nationally recognized for innovation in psychosocial care and creating a family-centered environment focused on the unique needs of hospitalized children and their families. Our love for children powers everything we do, inspiring our research, innovations and our everyday care. Because love has no limits. And with it, neither do we.